Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10217331,EC50,"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[ng] / [ml],1.35,21557,DB00986,Glycopyrrolate
,10217331,rate constant (k(e0)),"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[l] / [h],11.0,21558,DB00986,Glycopyrrolate
,32428247,flow-rate,"The eluate was directly injected into an Agilent Pursuit 5PFP column for analysis using an isocratic mobile phase of 50:50 A:B at a flow-rate of 0.500 ml/min (A, 10 mm ammonium acetate in 1% formic acid; B, methanol).",Validation of a sensitive and specific LC-MS/MS method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32428247/),[ml] / [min],0.500,32855,DB00986,Glycopyrrolate
,32428247,bioavailabilities,"By comparison with intravenous administration, respective bioavailabilities of ~15% for GLY/Magnair and ~22% for the Seebri Breezhaler were found.",Validation of a sensitive and specific LC-MS/MS method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32428247/),%,15,32856,DB00986,Glycopyrrolate
,32428247,bioavailabilities,"By comparison with intravenous administration, respective bioavailabilities of ~15% for GLY/Magnair and ~22% for the Seebri Breezhaler were found.",Validation of a sensitive and specific LC-MS/MS method and application to evaluate the systemic exposure and bioavailability of glycopyrrolate via different drug delivery approaches/devices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32428247/),%,22,32857,DB00986,Glycopyrrolate
,8431344,peak plasma lignocaine concentration,"The mean (SD) peak plasma lignocaine concentration was 0.57 (0.29) microgram ml-1 after glycopyrronium and 0.31 (0.10) microgram ml-1 after saline (P < 0.05) and were attained in 17 min (range 10-40 min) and 29 min (range 8-40 min), respectively.",Glycopyrronium prolongs topical anaesthesia of oral mucosa and enhances absorption of lignocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431344/),[μg] / [ml],0.57,39973,DB00986,Glycopyrrolate
,8431344,peak plasma lignocaine concentration,"The mean (SD) peak plasma lignocaine concentration was 0.57 (0.29) microgram ml-1 after glycopyrronium and 0.31 (0.10) microgram ml-1 after saline (P < 0.05) and were attained in 17 min (range 10-40 min) and 29 min (range 8-40 min), respectively.",Glycopyrronium prolongs topical anaesthesia of oral mucosa and enhances absorption of lignocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431344/),[μg] / [ml],0.31,39974,DB00986,Glycopyrrolate
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],70,54218,DB00986,Glycopyrrolate
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],2,54219,DB00986,Glycopyrrolate
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],140,54220,DB00986,Glycopyrrolate
,2077523,maximum plasma concentration (Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],14.26,54221,DB00986,Glycopyrrolate
,2077523,Tmax (time to Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),min,13.3,54222,DB00986,Glycopyrrolate
,23824662,peak sugammadex concentration,"The mean peak sugammadex concentration was 66.5 μg/mL, with exposure similar in the sevoflurane/propofol groups.",Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824662/),[μg] / [ml],66.5,65938,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],811.8,74209,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1748,74210,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],224.3,74211,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],459.3,74212,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1250,74213,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],2510,74214,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],315.4,74215,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],626.4,74216,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],27.20-29.40,74217,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],4.884-5.674,74218,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],69.49-77.08,74219,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],11.30-13.12,74220,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],46.49-53.58,74221,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],9.651-10.62,74222,DB00986,Glycopyrrolate
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],81.94-85.32,74223,DB00986,Glycopyrrolate
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],16.13-17.71,74224,DB00986,Glycopyrrolate
,2800994,distribution phase half-life,"Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h).",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),,2.22,97240,DB00986,Glycopyrrolate
,2800994,elimination phase half-life,"Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h).",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),h,0.83,97241,DB00986,Glycopyrrolate
,2800994,distribution volume during the elimination phase,"Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h).",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),[l] / [kg],0.64,97242,DB00986,Glycopyrrolate
,2800994,total plasma clearance,"Based on the plasma levels after a single intravenous injection, 6 micrograms/kg (n = 6), the distribution phase half-life (2.22 +/- 1.26 s.d. min) and the elimination phase half-life (0.83 +/- 0.29 h) of glycopyrrolate were short due to the low distribution volume during the elimination phase (0.64 +/- 0.29 l/kg) and to the respectively high total plasma clearance value (0.54 +/- 0.14 l/kg/h).",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),[l] / [h·kg],0.54,97243,DB00986,Glycopyrrolate
,2800994,time to maximum plasma concentration (tmax),In this group the time to maximum plasma concentration (tmax) was 27.48 +/- 6.12 min and the maximum plasma concentration (Cmax) was 3.47 +/- 1.48 micrograms/l.,Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),min,27.48,97244,DB00986,Glycopyrrolate
,2800994,maximum plasma concentration (Cmax),In this group the time to maximum plasma concentration (tmax) was 27.48 +/- 6.12 min and the maximum plasma concentration (Cmax) was 3.47 +/- 1.48 micrograms/l.,Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),[μg] / [l],3.47,97245,DB00986,Glycopyrrolate
,2800994,tmax,"After oral drug intake, 4 mg (n = 6), an apparently low and variable gastrointestinal absorption was found (tmax = 300.0 +/- 197.2 min, Cmax = 0.76 +/- 0.35 microgram/l), thus indicating that the oral route of drug administration is of no value as a routine premedication.",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),min,300.0,97246,DB00986,Glycopyrrolate
,2800994,Cmax,"After oral drug intake, 4 mg (n = 6), an apparently low and variable gastrointestinal absorption was found (tmax = 300.0 +/- 197.2 min, Cmax = 0.76 +/- 0.35 microgram/l), thus indicating that the oral route of drug administration is of no value as a routine premedication.",Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800994/),[μg] / [l],0.76,97247,DB00986,Glycopyrrolate
,24986094,tmax,Maximum plasma concentration (Cmax) of glycopyrronium was achieved shortly after inhalation (median tmax = 7 minutes).,"Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24986094/),min,7,108882,DB00986,Glycopyrrolate
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],33.2,110008,DB00986,Glycopyrrolate
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],61.3,110009,DB00986,Glycopyrrolate
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],33.6,110010,DB00986,Glycopyrrolate
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],20.0,110011,DB00986,Glycopyrrolate
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],436,110012,DB00986,Glycopyrrolate
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],925,110013,DB00986,Glycopyrrolate
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],4064,110014,DB00986,Glycopyrrolate
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],7195,110015,DB00986,Glycopyrrolate
,23506208,half-life,"The model suggested that the lung absorption of glycopyrronium was dominated by slow-phase absorption with a half-life of about 3.5 days, which accounted for 79% of drug absorbed through the lungs into the bloodstream, from where glycopyrronium was quickly eliminated.",Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506208/),d,3.5,112720,DB00986,Glycopyrrolate
,9783332,oral bioavailability,"Based on plasma levels determined with a radioreceptor assay and following a single oral (50 micrograms/kg) and intravenous (5 micrograms/kg) administration of glycopyrrolate in six healthy children operated twice during a several weeks period, a negligible and variable oral bioavailability was found (3.3; 1.3-13.3%) (median;range).",Pharmacokinetics and oral bioavailability of glycopyrrolate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783332/),%,3.3,113812,DB00986,Glycopyrrolate
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,152,118532,DB00986,Glycopyrrolate
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,240,118533,DB00986,Glycopyrrolate
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,165,118534,DB00986,Glycopyrrolate
,24325462,plasma clearance (Clp),"The median (range) plasma clearance (Clp), volume of distribution of the central compartment (V1 ), volume of distribution at steady-state (Vss), and area under the plasma concentration-time curve (AUC0-inf ) were 16.7 (13.6-21.7) mL/min/kg, 0.167 (0.103-0.215) L/kg, 3.69 (0.640-38.73) L/kg, and 2.58 (2.28-2.88) ng*h/mL, respectively.",The pharmacokinetics of glycopyrrolate in Standardbred horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24325462/),[ml] / [kg·min],16.7,123051,DB00986,Glycopyrrolate
,24325462,volume of distribution of the central compartment (V1 ),"The median (range) plasma clearance (Clp), volume of distribution of the central compartment (V1 ), volume of distribution at steady-state (Vss), and area under the plasma concentration-time curve (AUC0-inf ) were 16.7 (13.6-21.7) mL/min/kg, 0.167 (0.103-0.215) L/kg, 3.69 (0.640-38.73) L/kg, and 2.58 (2.28-2.88) ng*h/mL, respectively.",The pharmacokinetics of glycopyrrolate in Standardbred horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24325462/),[l] / [kg],0.167,123052,DB00986,Glycopyrrolate
,24325462,area under the plasma concentration-time curve (AUC0-inf ),"The median (range) plasma clearance (Clp), volume of distribution of the central compartment (V1 ), volume of distribution at steady-state (Vss), and area under the plasma concentration-time curve (AUC0-inf ) were 16.7 (13.6-21.7) mL/min/kg, 0.167 (0.103-0.215) L/kg, 3.69 (0.640-38.73) L/kg, and 2.58 (2.28-2.88) ng*h/mL, respectively.",The pharmacokinetics of glycopyrrolate in Standardbred horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24325462/),[h·ng] / [ml],2.58,123053,DB00986,Glycopyrrolate
,24325462,Renal clearance,Renal clearance of GLY was characterized by a median (range) of 2.65 (1.92-3.59) mL/min/kg and represented approximately 11.3-24.7% of the total plasma clearance.,The pharmacokinetics of glycopyrrolate in Standardbred horses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24325462/),[ml] / [kg·min],2.65,123054,DB00986,Glycopyrrolate
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.95,145894,DB00986,Glycopyrrolate
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.75,145895,DB00986,Glycopyrrolate
,16170596,half-life,"Following i.v. administration in rats, it was very rapidly eliminated, mainly through renal excretion with a half-life of about 10 min.",Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16170596/),min,10,148791,DB00986,Glycopyrrolate
,26428357,time to reach maximum concentration (T max),Median time to reach maximum concentration (T max) was reached within 5 min after inhalation on both Days 1 and 14.,Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428357/),min,5,151425,DB00986,Glycopyrrolate
,26428357,"effective half-life (T 1/2,acc)","Mean effective half-life (T 1/2,acc) was 37.7 h.",Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26428357/),h,37.7,151426,DB00986,Glycopyrrolate
,2400072,maximum plasma concentration (Cmax),"A fast absorption rate was found with a mean maximum plasma concentration (Cmax) of 6.3 (SD 1.5) ng/ml, a mean time to Cmax (Tmax) of 10.0 (3.8) minutes and the elimination half-life (t1) of 33.4 (1.92).",Pharmacokinetics of glycopyrronium in parturients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400072/),[ng] / [ml],6.3,155363,DB00986,Glycopyrrolate
,2400072,time to Cmax (Tmax),"A fast absorption rate was found with a mean maximum plasma concentration (Cmax) of 6.3 (SD 1.5) ng/ml, a mean time to Cmax (Tmax) of 10.0 (3.8) minutes and the elimination half-life (t1) of 33.4 (1.92).",Pharmacokinetics of glycopyrronium in parturients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400072/),min,10.0,155364,DB00986,Glycopyrrolate
,2400072,elimination half-life (t1),"A fast absorption rate was found with a mean maximum plasma concentration (Cmax) of 6.3 (SD 1.5) ng/ml, a mean time to Cmax (Tmax) of 10.0 (3.8) minutes and the elimination half-life (t1) of 33.4 (1.92).",Pharmacokinetics of glycopyrronium in parturients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400072/),,33.4,155365,DB00986,Glycopyrrolate
,2400072,AUC0-8 h,The respective AUC0-8 h value was 5.61 (1.27) hours ng/ml.,Pharmacokinetics of glycopyrronium in parturients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400072/),[h·ng] / [ml],5.61,155366,DB00986,Glycopyrrolate
,33152467,Cmax,The exception was that Cmax for glycopyrrolate was slightly lower in Asian versus Western subjects (0.6-0.7).,Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33152467/),,0.6-0.7,155773,DB00986,Glycopyrrolate
,3733273,t1/2,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),min,1-2,156391,DB00986,Glycopyrrolate
,3733273,Vd beta,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [kg],2.6,156392,DB00986,Glycopyrrolate
,3733273,Cl total,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [h·kg],0.310-0.384,156393,DB00986,Glycopyrrolate
,3733273,elimination phase half-life,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),h,6.5,156394,DB00986,Glycopyrrolate
,31253162,absolute systemic bioavailability,"Without charcoal, the absolute systemic bioavailability of GLY/eFlow and GLY/DPI were approximately 15 and 22%, respectively.",Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31253162/),%,15,160596,DB00986,Glycopyrrolate
,31253162,absolute systemic bioavailability,"Without charcoal, the absolute systemic bioavailability of GLY/eFlow and GLY/DPI were approximately 15 and 22%, respectively.",Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31253162/),%,22,160597,DB00986,Glycopyrrolate
,22257577,time to reach maximal plasma concentration (tmax),The median time to reach maximal plasma concentration (tmax) was 5 or 6.5 min postinhalation.,Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257577/),min,5,185675,DB00986,Glycopyrrolate
,22257577,time to reach maximal plasma concentration (tmax),The median time to reach maximal plasma concentration (tmax) was 5 or 6.5 min postinhalation.,Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257577/),min,6.5,185676,DB00986,Glycopyrrolate
,22257577,terminal elimination half-life (t1/2),The mean terminal elimination half-life (t1/2) of NVA237 ranged between 13 and 22 h.,Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257577/),h,13 and 22,185677,DB00986,Glycopyrrolate
,22257577,Renal clearance (CLR),"Renal clearance (CLR) was similar across doses both after single and repeated dosing, ranging between 17.4 and 20.6 l/h.",Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257577/),[l] / [h],17.4 and 20.6,185678,DB00986,Glycopyrrolate
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1598.38,202225,DB00986,Glycopyrrolate
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1657.09,202226,DB00986,Glycopyrrolate
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1276.75,202227,DB00986,Glycopyrrolate
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.16,202228,DB00986,Glycopyrrolate
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.53,202229,DB00986,Glycopyrrolate
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],23.24,202230,DB00986,Glycopyrrolate
,2378771,elimination half-life,"Rapid absorption was found, with a mean peak plasma concentration after 16.1 min and mean elimination half-life of 75.4 min.",Pharmacokinetics of i.m. glycopyrronium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378771/),min,75.4,207055,DB00986,Glycopyrrolate
,34085852,m/,MS/MS detection was at ESI+ by monitoring m/z 318.3→116.1 for GLY and 321.3→119.1 for the internal standard GLY-d3.,An ultrasensitive LC-MS/MS method and application to clinical dose-range finding for glycopyrrolate via an e-Nebulizer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34085852/),,318.3,230388,DB00986,Glycopyrrolate
,34085852,m/,MS/MS detection was at ESI+ by monitoring m/z 318.3→116.1 for GLY and 321.3→119.1 for the internal standard GLY-d3.,An ultrasensitive LC-MS/MS method and application to clinical dose-range finding for glycopyrrolate via an e-Nebulizer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34085852/),,116.1,230389,DB00986,Glycopyrrolate
,34085852,m/,MS/MS detection was at ESI+ by monitoring m/z 318.3→116.1 for GLY and 321.3→119.1 for the internal standard GLY-d3.,An ultrasensitive LC-MS/MS method and application to clinical dose-range finding for glycopyrrolate via an e-Nebulizer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34085852/),,321.3,230390,DB00986,Glycopyrrolate
,27841152,t<sub>max</sub>,"Both IND and GLY were absorbed rapidly after inhalation of IND/GLY (t<sub>max</sub>: IND, 15 minutes; GLY, 5 minutes).",Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841152/),min,15,231702,DB00986,Glycopyrrolate
,27841152,t<sub>max</sub>,"Both IND and GLY were absorbed rapidly after inhalation of IND/GLY (t<sub>max</sub>: IND, 15 minutes; GLY, 5 minutes).",Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841152/),min,5,231703,DB00986,Glycopyrrolate
,27841152,accumulation ratio,"Accumulation through systemic exposure of both IND and GLY from day 1 to day 14 was observed (mean accumulation ratio (R<sub>acc</sub>) of AUC<sub>0-24h</sub> (day 14/day 1): IND, 3.02; GLY 2.94; estimated accumulation ratio of C<sub>max</sub>: IND 1.56; GLY 1.33).",Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841152/),,1.56,231704,DB00986,Glycopyrrolate
,27841152,"effective half-life (t<sub>1/2,acc</sub>","Mean effective half-life (t<sub>1/2,acc</sub>) was 41.3 h and 40.0 h for IND and GLY, respectively.",Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841152/),h,41.3,231705,DB00986,Glycopyrrolate
,27841152,"effective half-life (t<sub>1/2,acc</sub>","Mean effective half-life (t<sub>1/2,acc</sub>) was 41.3 h and 40.0 h for IND and GLY, respectively.",Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27841152/),h,40.0,231706,DB00986,Glycopyrrolate
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,95,243682,DB00986,Glycopyrrolate
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,107,243683,DB00986,Glycopyrrolate
,8398530,renal excretion,The 24-h renal excretion was 7 (0-25)% in uraemic and 65 (30-99)% in control patients (P < 0.001).,Pharmacokinetics of glycopyrronium in uraemic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398530/),%,7,250476,DB00986,Glycopyrrolate
,8398530,renal excretion,The 24-h renal excretion was 7 (0-25)% in uraemic and 65 (30-99)% in control patients (P < 0.001).,Pharmacokinetics of glycopyrronium in uraemic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398530/),%,65,250477,DB00986,Glycopyrrolate
>,24928173,duration of,"In vitro, aclidinium, glycopyrronium and tiotropium had a long duration of action at native M3 receptors (>8 h versus 42 min for ipratropium).",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,8,268623,DB00986,Glycopyrrolate
,24928173,duration of,"In vitro, aclidinium, glycopyrronium and tiotropium had a long duration of action at native M3 receptors (>8 h versus 42 min for ipratropium).",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),min,42,268624,DB00986,Glycopyrrolate
,24928173,time to 50% recovery of effect [t½ offset],"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,29,268625,DB00986,Glycopyrrolate
,24928173,time to 50% recovery of effect [t½ offset],"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,13,268626,DB00986,Glycopyrrolate
,24928173,t½ offset,"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,64,268627,DB00986,Glycopyrrolate
,24928173,t½ offset,"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,8,268628,DB00986,Glycopyrrolate
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],38,268629,DB00986,Glycopyrrolate
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],0.74,268630,DB00986,Glycopyrrolate
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],0.88,268631,DB00986,Glycopyrrolate
